on start you I'm my progress of with And and give listening the will I Yes. to Thank in Adi, clinical everyone our AFMXX. you, update phone also of welcome programs. for three And the from here, in. progress thanks happy an to the side.
clearance proceed product. combination with to the be NK FDA As we of from allogeneic the have told a the will call, ABXXX, initiation which in trial, X you cell with clinical we on our Phase evaluated received last AFMXX in
have We getting sites and our to XX of towards and have dedication this the study treatment. over participate, the progress commitment generated made and running innovative U.S. up showing advancing our in interest to goal from significant
are We stages now activation first and expect in the final recruitment open the patient timeframe. of have the to for September-October site sites in
the Importantly, to will of that we from initial report XXXX. us this in believe half study the data first enable
active ABXXX, efficacy this and even treatment already regimen. provide of data will into and patients all be we update this meaningful insight treated safety both believe will of As initial doses with cohorts, the initial AFMXX in a
scheduled agency. have with mentioned, purpose meeting to Furthermore, FDA, we steps have Type the meeting the to and as guidelines, requested for be meeting up Adi proactive FDA to is accelerated quarter follow with we this taken the to on C the discuss further of and approval of an The based requirements Based XXXX. expect the fourth study. on engage XXX a in LuminICE-Liminise
clinical shown on study and X. is design Our Slides X proposed
doses doses. note with different Slide that four finally, two schedule the first next study that of on doses shown Simon Hodgkin's part. use lymphoma. ABXXX, important is cohorts As to for the of four on we two X, It's focusing classical with ABXXX, different part Design. step, And the and our and these of all of of active then four to doses the final selected refractory believe will are relapsed Two-Stage patients will doses cohorts respectively select expansion the for AFMXX intention and Two be will one AFMXX commence evaluating
to FDA's addresses to the market. design development the and on doses guidance dose course This the early on different generate informed be that developed will make in decisions of fully clinical data for
guidelines. As example, for in Project outlined the Optimus
T-cell CDXX commence fifth positive, next and to addition, treating cohort start In year. this should lymphomas, we peripheral plan a cohort
planned Slide doses patients three After a applications individual tested design weekly you times, be multiple the On that when study. will cells safe cell has demonstrated cell-mediated offer It of fludarabine, the and our on been and once cycles of to cytotoxicity. three application the receive NK patients followed on weekly with experience and up agent. study. builds of AFMXX-XXX in single by the ABXXX of and weeks to lymphodepleting regimen weekly, longer exposure AFMXX even NK cycle with give AFMXX X, show more who to This studies may cells cyclophosphamide consecutive of design AFMXX modest The and experience on to is NK other used tumor therapy a see response. in three from treatment to an
has attack weekly, combination refractory in of note, (ph) promising [rituximab] and good capable is as with XXX the patients ASCO. could cells, is a early own three thus weekly The with on activity the it weeks AFMXX Of patients' application safety at to shown recently of published that based in B-cell profile again, lymphomas from additional ABXXX, be tumor. three on AFMXX load for providing dual study, given NK data shown where repopulating data
are interval cycles, tumor reducing of cells We between regrowth also cycles. thereby the preventing between
think remissions difficult-to-treat we lasting in deep that these us together, the to the design produce and best study chance Taken gives patients.
as of NK later already the is data will efficacy, study analysis outcomes Anderson with combination expect durability, XXX This a potential at as this study from cells. provide Adi demonstrating data in safety lymphomas, observed Additionally, far in with CDXX-positive year. mentioned, the patients MD we the to ASH further as of updated concerned, this present and comprehensive AFMXX
let's now And to return AFMXX.
that focus study our will development no know, failed with we with with lines the study, mutant cell and atezolizumab note, late-line and prior clinical AFMXX near non-small treatment you in options. further Important have cancer, cancer. EGFR AFMXX as AFMXX announced combination monotherapy patients that this renal term. ASCO have were program in As we investigated our in multiple cell carcinoma, In during to on the colorectal treating lung we often patients
on clear shown data Slide At that X. activity presented showed we cohorts. three signs across ASCO, As all of
lung stable patients additional the shrinkage by partial reduction. responses, could tumor encouraged stable pretreated with cancer, partial particularly disease, heavily includes volume patients are mutant which EGFR produce cell patients five three AFMXX two confirmed We that responses in diseases with with non-small and including and tumor
being favorable targeting manageable AFMXX reactions infusion-related Importantly, side not skin in did safety agents. AFMXX mucosa, exhibited or is the severe associated other a common induce with effect. with toxicity most EGFR commonly the EGFR-mediated which profile,
target patients or across earlier, tumor investigated and also colorectal in the lesions the tumor both and demonstrated types. again, data shrinkage reductions cell with said cancer carcinoma, study As renal
another patients including, substantial achieving these of just shy XX% of of target their carcinoma cell stability in for lesions, showed reduction Some renal disease, example, once-progressive one response. patient, partial a prolonged
based atezolizumab. cohort for study regulatory with earlier As Based a the this on on cell combination encouraging ongoing to open enrollment. now fourth agencies, of cancer, XX, we cohort Slide shown on non-small EGFR-mutated AFMXX filed with lung amendment activity monotherapy, in very have an the added patient is
the and activating cells, cells is immune by in to Moving by specifically macrophages and role tumor-associated be NK believe liberate system forward, shown can we to then clonal in leading macrophages and antigens the studies. dendritic activation These and tumor of triggering destroy T-cells, that tumor-reactive as expansion earlier AFMXX's cells processed antigens our crucial.
which activates atezolizumab, therefore The immune a the combination immune enhances of innate with the adaptive system rationale. AFMXX, which logical system, has
also trial mentioned, present with Adi the from a atezolizumab at an fourth combination to plan ongoing we As in the update quarter. event company
Finally, were this mean therapy data and were combination novel Breakthrough. AFMXX lines the the NK AFMXX, combination combination feasibility with prior study, NK first of believe at this portion to from a or human in ICE In the PK establish – five AFMXX similar of approach. autologous escalation properties in dose combination SNKXX received monotherapy. cell of was an of product SNKXX. No observed, of patients the study of cell recently cell with presented product the of seven number unexpected adaptive with AFMXX this transfer We ASCO toxicities that dose-limiting
clinically stabilization of investigator, better disease was stable will combination suited options this advance lead believe study, note, learnings we AFMXX. Based NK we considered cancer pretreated cell from the AFMXX product, heavily with with is on by patients which the to off-the-shelf evaluating meaningful. Of the with colorectal for an are our be microsatellite in [indiscernible] allogeneic
Slide on myeloid CDXXX-positive including address update and which designed we Let's to of providing now the is specifically turn myeloid leukemia. AFMXX, are XX to AFMXX, acute malignancies,
We in progress have advancing AFMXX. of made clinical the development significant
weekly administering highlights these Building dose-limiting XX development the we we AFMXX First, third heavily are we patients. have weekly any on favorable started This cohort, milligram cohort, to of successfully tolerability flat to patients AML, encountering profile and second cleared administering once dose pretreated of milligrams have data, AFMXX. XXX toxicities. AML without safety the now where with dose the positive
a targeting a new In toxicity. We minimal targeting stem engagers being Moreover, programs. we profile. by CDXXX as the target drug other terminations is fatal engager, assessments, expressed CDXXX were such not data at target, This engagers, highly with further important, possible This drugable acceptable but target our is only have including NK of as blasts, at these as validated safety with presented as also this is cell also considered patients. or leading cases likely high importance, therapeutic results also the believe AFMXX doses, a that CAR-Ts, ASCO cell and target NK encouraged of promising mean on toxicity, emphasize CDXXX, cells. of an potential often approaches, on data with leukemic as that leukemic shown these for different low AML to conjugates a antibody T-cell many CDXXX-directed showcased is
NK earlier Conference data even stem the cells. blasts of of associated data remained this highlighted with Additionally, at and AFMXX believe Blood characteristics antitumor unaffected lysis expression European remissions promise safe of activity, demonstrated on leukemic at from Marrow AFMXX. deeper frequent the Notably, suggest cells. exhibited The year the Transplantation levels CDXX activity for profile. CDXXX a more and low induction preclinical the presented cell-mediated expression AFMXX AML effective and We distinguish of by Society the toxicity other possibility and these approaches leukemic and
Given for of working are to we patients. need refractory AML nature viable options, the the availability of treatment the diligently AFMXX expedite and urgent relapsed for AML aggressive and
please. quarterly I With to on numbers. update Angus, progress clinical and the update on my the to will turn call financial over this, you conclude Angus the
